Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
TC-6987 is a selective nicotinic α-7 receptor ligand (open channel stabilizer) that has
demonstrated potent anti-inflammatory/antioxidant properties in animal models. Following the
oral administration of a 1mg/kg dose of TC-6987 to diabetic mice (db/db mouse) for 7 weeks,
numerous metabolic improvements were observed. Specifically, plasma glucose and triglyceride
concentrations declined by approximately 30%; Hb1Ac was reduced by nearly 50%; and TNF-α
declined more than 60% relative to control db/db mice Therefore, it appears that TC-6987
could prove beneficial in reducing elevated glucose concentrations in diabetic patients as
well as in ameliorating organ damage associated with inflammation, oxidative stress and
hyperglycemia.